20 May 2026

Optimal timing of aspirin discontinuation: when early is too early?

Session comprising selected EuroPCR 2026 abstract submissions

Moderators: D. Giacoppo, S. Nijjer

Speakers: M. Spagnolo, Y. J. Ki, V. Oliveira, M. Singh, O. Angeras, K. Bujak

Summary

This session critically evaluates the optimal timing for aspirin discontinuation after PCI, discussing outcomes of aspirin-free strategies initiated within one month versus three months post-procedure. It considers differential effects of DAPT duration based on ACS presentation and bleeding risk, supported by meta-analyses and real-world data to guide personalized antiplatelet therapy decisions.

Presentations available when logged in:

Outcomes of transition to aspirin-free strategies within one month vs. three months after PCI
Differential effects of DAPT duration according to ACS presentation and bleeding risk
Early aspirin discontinuation following PCI for ACS: a reconstructed IPD meta-analysis
Real-world use of abbreviated DAPT after PCI in high bleeding risk patients
Ticagrelor monotherapy after coronary stenting in AMI - 12 months results
Optimal timing of aspirin withdrawal in P2Y12 inhibitor monotherapy after ACS

Your free My PCR account will enable you to:

Become a PCR Companion
Access slide presentations from PCR Courses
Watch session videos and LIVE cases
Discuss cases with your peers
Submit and register for PCR Courses
Register for and view PCR Webinars
Read a selection of articles in EuroIntervention
And more…

Optimal timing of aspirin discontinuation: when early is too early?

Session comprising selected EuroPCR 2026 abstract submissions

Log in or create account for free